jRCT2031240171招募中不适用
A Phase 2a, Randomized, Evaluator-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010905 Ophthalmic Suspension Compared with Placebo in Subjects with MGD
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Single Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Outpatient
- •Diagnosed as MGD based on the guideline
- •Having ocular symptoms
排除标准
- •Ocular disease which needs treatment expect MGD and dry eye
- •Requires contact lenses wear during the study
- •Any decision by the Investigator to terminate a subject in screening
结局指标
主要结局
-
Evaluation of meibomian gland by idra
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A study assessing the efficacy and safety of an investigational drug called fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsEUCTR2020-002858-24-SEClementia Pharmaceuticals Inc, an Ipsen Company98
尚未招募
2 期
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsNL-OMON54489Ipsen Pharmaceuticals5
招募中
2 期
A study assessing the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for FOPfibrodysplasia ossificans progressivaJPRN-jRCT2041220080egar Karimian4
招募中
1 期
A Phase 2 Study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participants.Fibrodysplasia Ossificans ProgressivaCTIS2024-511469-13-00Clementia Pharmaceuticals Inc. An Ipsen Company98
进行中（未招募）
1 期
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsfibrodysplasia ossificans progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-002858-24-NLClementia Pharmaceuticals Inc, an Ipsen Company98